We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Going into Phase III trials, Menlo Park, California-based Dermira, Inc. and numerous investors were optimistic about the company’s olumacostat glasaretil for acne.